Paroxysmal Nocturnal Haemoglobinuria
📧 Sign up to get email alerts when something new happens for Paroxysmal Nocturnal Haemoglobinuria.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Real-life Treatment Outcomes of Ravulizumab in PNH
This study reports real-world treatment outcomes of Ravulizumab in patients with paroxysmal nocturnal haemoglobinuria.
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia [Phase 3]
A Phase 3 trial evaluating HSK39297 in anti-C5–treated patients with paroxysmal nocturnal haemoglobinuria and anemia has completed to assess…
-
CLINICAL_TRIALS research · 2025-05-09Clinical Trial Update: Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy [Phase 3]
Phase 3 clinical trial update for MY008211A in patients with paroxysmal nocturnal haemoglobinuria who are naive to complement inhibitor ther…
-
EMA approval · 2024-03-22First oral monotherapy for patients with paroxysmal nocturnal haemoglobinuria
EMA has recommended EU marketing authorization for Fabhalta (iptacopan), an oral monotherapy for adults with paroxysmal nocturnal haemoglobi…
-
EMA approval · 2024-02-23First oral treatment against residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria
EMA recommends marketing authorization for Voydeya, the first oral treatment for Paroxysmal nocturnal haemoglobinuria patients with residual…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.